JHS Svendgaard Laboratories Ltd
JHS Svendgaard Laboratories Ltd (JHS) last reported results for the quarter ended Jun 2026, with sales of ₹30.38 crore and net profit of ₹1.09 crore. The stock last traded at ₹10.1, a market capitalisation of ₹88.3 crore. Over the past 52 weeks the stock has ranged between ₹6.15 and ₹13.9. Figures are as of 6 Oct 2026 and are not real time.
JHS Svendgaard Laboratories Ltd share price and key metrics
- Current price
- ₹10.1
- Market cap
- ₹88.3 cr
- Book value
- ₹20
- ROE
- -1.17%
- ROCE
- -0.84%
- Dividend yield
- 0.00%
- 52w high / low
- 13.9/6.15
Metrics as of 6 Oct 2026. Not real time.
Track JHS Svendgaard Laboratories Ltd
Cruxal reads every JHS Svendgaard Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
JHS Svendgaard Laboratories Ltd growth and returns
- 10 Years
- 0%
- 5 Years
- 0%
- 3 Years
- 6%
- TTM
- 19%
- 10 Years
- 4%
- 5 Years
- %
- 3 Years
- %
- TTM
- 88%
- 10 Years
- -11%
- 5 Years
- -17%
- 3 Years
- -22%
- 1 Year
- -10%
- 10 Years
- 2%
- 5 Years
- -1%
- 3 Years
- -5%
- Last Year
- -1%
JHS Svendgaard Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹30.38 cr, up 29.6% from ₹23.45 cr a year earlier. Net profit was ₹1.09 cr, up 2.8% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 19.68 | 22.66 | 25.17 | 23.45 | 22.28 | 23.27 | 32.7 | 30.38 |
| Expenses | 20.52 | 22.41 | 30.55 | 21.79 | 21.37 | 21.6 | 34.34 | 28.31 |
| Operating profit | -0.84 | 0.25 | -5.38 | 1.66 | 0.91 | 1.67 | -1.64 | 2.07 |
| OPM % | -4.27% | 1.10% | -21.37% | 7.08% | 4.08% | 7.18% | -5.02% | 6.81% |
| Other income | 0.86 | 0.27 | -1.44 | 1 | 1.14 | 0.59 | 0.73 | 0.09 |
| Interest | 0.11 | 0.13 | 0.21 | 0.16 | 0.2 | 0.28 | 0.22 | 0.28 |
| Depreciation | 1.98 | 1.97 | 2.02 | 1.88 | 1.86 | 1.9 | 1.86 | 1.82 |
| Profit before tax | -2.07 | -1.58 | -9.05 | 0.62 | -0.01 | 0.08 | -2.99 | 0.06 |
| Tax % | 398.07% | 15.82% | -23.09% | -69.35% | 1,800.00% | -887.50% | 19.73% | -1,716.67% |
| Net profit | -10.32 | -1.84 | -6.96 | 1.06 | -0.2 | 0.79 | -3.57 | 1.09 |
| EPS (₹) | -1.21 | -0.21 | -0.81 | 0.12 | -0.02 | 0.09 | -0.41 | 0.12 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
JHS Svendgaard Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 104 | 140 | 124 | 139 | 101 | 86 | 85 | 71 | 92 | 102 | 109 |
| Operating profit | 12 | 14 | 0 | 2 | 2 | -1 | -9 | -1 | -4 | 3 | 3 |
| OPM % | 11% | 10% | 0.1% | 1.2% | 1.9% | -1.0% | -11% | -1.3% | -4.4% | 2.6% | 2.8% |
| Net profit | 22 | 26 | -2 | -5 | 1 | -4 | -18 | -4 | -20 | -2 | -2 |
| EPS (₹) | 4.98 | 4.29 | -0.11 | -0.33 | 0.19 | -0.62 | 0.62 | -0.52 | -2.31 | -0.22 | -0.22 |
TTM is the trailing twelve months to the most recent quarter.
JHS Svendgaard Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 44 | 61 | 61 | 61 | 64 | 65 | 78 | 78 | 86 | 87 |
| Reserves | 90 | 113 | 116 | 117 | 124 | 121 | 95 | 91 | 87 | 87 |
| Borrowings | 2 | 2 | 7 | 9 | 7 | 6 | 3 | 5 | 6 | 15 |
| Other liabilities | 19 | 32 | 39 | 55 | 33 | 30 | 52 | 22 | 25 | 27 |
| Total liabilities | 155 | 208 | 223 | 241 | 228 | 222 | 228 | 197 | 204 | 216 |
| Fixed assets | 65 | 71 | 71 | 66 | 63 | 59 | 65 | 90 | 90 | 89 |
| CWIP | 1 | 1 | 5 | 7 | 9 | 20 | 9 | 1 | 0 | 4 |
| Investments | 1 | 18 | 10 | 6 | 2 | 4 | 3 | 3 | 4 | 5 |
| Other assets | 89 | 118 | 137 | 163 | 154 | 140 | 152 | 102 | 110 | 118 |
| Total assets | 155 | 208 | 223 | 241 | 228 | 222 | 228 | 197 | 204 | 216 |
As reported by the company. Total assets equal total liabilities by construction.
JHS Svendgaard Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -4 | 14 | -11 | 10 | 12 | -9 | 23 | -9 | -5 | -3 |
| Cash from investing | -3 | -27 | -7 | -11 | -2 | -5 | 10 | -21 | -20 | -12 |
| Cash from financing | 10 | 14 | 13 | 0 | 10 | -2 | -1 | 2 | 23 | 11 |
| Net cash flow | 3 | 0 | -5 | -0 | 20 | -16 | 32 | -28 | -2 | -3 |
| Free cash flow | -17 | 3 | -26 | 0 | 5 | -16 | 21 | -33 | -14 | -15 |
| CFO / operating profit | -33% | 119% | -10,000% | 595% | 650% | 1,051% | -257% | 1,001% | 122% | -77% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
JHS Svendgaard Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 5% | 8% | -0% | 4% | 1% | 1% | -2% | -2% | -5% | -1% |
| Debtor days | 48 | 111 | 158 | 252 | 213 | 77 | 80 | 66 | 52 | 60 |
| Inventory days | 95 | 65 | 60 | 30 | 97 | 114 | 128 | 176 | 151 | 156 |
| Days payable | 123 | 153 | 134 | 177 | 128 | 130 | 197 | 197 | 140 | 174 |
| Cash conversion cycle | 19 | 23 | 85 | 105 | 182 | 61 | 11 | 46 | 63 | 42 |
| Working capital days | 56 | 122 | 173 | 198 | 272 | 217 | 41 | 51 | 47 | 45 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
JHS Svendgaard Laboratories Ltd shareholding pattern
Promoters held 33.85% at Jun 2026, down from 34.56% at Jun 2025. FIIs 3.14% and DIIs 0.00%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 34.56% | 34.56% | 34.56% | 34.56% | 34.56% | 34.56% | 33.85% | 33.85% |
| FIIs | 1.69% | 1.59% | 1.60% | 1.59% | 1.57% | 1.57% | 3.60% | 3.14% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 63.76% | 63.85% | 63.84% | 63.86% | 63.87% | 63.86% | 62.57% | 63.03% |
| No. of shareholders | 25,994 | 26,276 | 25,567 | 25,155 | 25,007 | 25,151 | 25,330 | 25,150 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
JHS Svendgaard Laboratories Ltd corporate filings
- Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018Company Updatelow impact
- Scrutinizer Report for the 22nd AGM held on 26th September, 2026AGM/EGMmedium impact
- JHS Svendgaard Laboratories Limited concludes 22nd Annual General Meeting with no audit qualificationsAGM/EGMlow impact
Cruxal's analysis: JHS Svendgaard Laboratories Limited held its 22nd Annual General Meeting on September 26…
Read the full analysis - Intimation of Closure of Trading window for the Quarter and Half Year ended September 30th, 2026.Insider Trading / SASTlow impact
- JHS Svendgaard Laboratories Ltd issues notice for Annual Report 2025-26 distributionCompany Updatelow impact
Cruxal's analysis: JHS Svendgaard Laboratories Ltd has issued a notification regarding the distribution of…
Read the full analysis - JHS Svendgaard Laboratories Limited Announces 22nd Annual General Meeting for September 26, 2026Company Updatelow impact
Cruxal's analysis: JHS Svendgaard Laboratories Limited has issued a formal notice for its 22nd Annual…
Read the full analysis - JHS Svendgaard Laboratories Limited Announces 22nd Annual General Meeting for September 26, 2026AGM/EGMlow impact
Cruxal's analysis: JHS Svendgaard Laboratories Limited has issued a notice for its 22nd Annual General…
Read the full analysis - JHS Svendgaard Laboratories Ltd files Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: JHS Svendgaard Laboratories Ltd has submitted its Annual Report for the financial year…
Read the full analysis - JHS Svendgaard Laboratories Ltd announces newspaper publication regarding Annual General MeetingCompany Updatelow impact
Cruxal's analysis: JHS Svendgaard Laboratories Limited has fulfilled regulatory requirements under…
Read the full analysis - JHS Svendgaard Laboratories Limited reports Q1 FY2027 financial results with return to profitabilityCompany Updatehigh impact
Cruxal's analysis: JHS Svendgaard Laboratories Limited has released its unaudited financial results for the…
Read the full analysis - JHS Svendgaard Laboratories Ltd files Statement of Deviation and Variation for quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: The company has submitted its Statement of Deviation and Variation for the quarter ended…
Read the full analysis - JHS Svendgaard Laboratories reports Q1 FY27 standalone net profit of 1.09 crore, turning profitable YoYResulthigh impact
Cruxal's analysis: JHS Svendgaard Laboratories Limited reported a turnaround in its financial performance…
Read the full analysis - JHS Svendgaard Laboratories Limited schedules Board Meeting for August 11, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: JHS Svendgaard Laboratories Limited has issued a formal intimation regarding a Board of…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.